MedTrace Logo

Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

NCT05478538 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-04-29

No results posted yet for this study

Summary

The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform using in-vivo RECIST 1.1 as the reference method.

Conditions

  • NSCLC (Non-small Cell Lung Cancer)
  • Metastatic NSCLC - Non-Small Cell Lung Cancer

Interventions

PROCEDURE

Core Needle, Forceps, or Punch Biopsy

Subjects must be clinically able, at investigator discretion, to undergo additional core needle, forceps, or punch biopsy during their biopsy. These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.

Sponsors & Collaborators

  • Elephas

    lead INDUSTRY

Principal Investigators

  • Fred Hausheer, MD, FACP · Elephas

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-31
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05478538 on ClinicalTrials.gov